N-terminal pro-brain natriuretic peptide

Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide a new gold standard in predicting mortality in patients with advanced heart failure. E Heart J 2003 24 1735-43. 

Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 2003 42 1909-16. 

Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002 40 437-45. 

Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomeduUin new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998 97 1921-9. 

C-type natriuretic peptide (CNP) the newest member of the natriuretic peptide family, was first isolated from porcine brain, and later found in other mammals and nonmammals. It is processed from a pre-pro-CNP molecule, which gives rise to CNP-22 and its N-terminally elongated form. CNP-53. The CNP s share considerable sequence homology with atrial NATRIURETIC PEPTIDES (ANP) and brain natriuretic peptides (BNP). CNP s are atrial NATRIURETIC PEPTIDE RECEPTOR AGONISTS but are more active at the type-B subtype, whereas ANP s are more active at the type-A subtype. 

---